Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Leaders from across the NHS, government, industry and academia have called for a fundamental shift in how artificial intelligence is adopted across the health service, arguing that the NHS must move beyond isolated pilots and create clearer, faster routes to…
Health Innovation Kent Surrey Sussex (KSS) and Doctors Training have co-designed and co-delivered Generative AI (GenAI) training for NHS clinical staff, ensuring ethical, scalable, and high-quality workforce education.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us